PFS Group S.L. Revenue and Competitors

Madrid, Spain

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • PFS Group S.L.'s estimated annual revenue is currently $61.3M per year.(i)
  • PFS Group S.L.'s estimated revenue per employee is $181,250

Employee Data

  • PFS Group S.L. has 338 Employees.(i)
  • PFS Group S.L. grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M132-7%N/AN/A
#2
$17.8M12322%N/AN/A
#3
$19.6M13525%N/AN/A
#4
$3.6M31-31%N/AN/A
#5
$4.2M36-18%N/AN/A
#6
$13.3M92-29%N/AN/A
#7
$16.2M1126%N/AN/A
#8
$0.6M8-33%N/AN/A
#9
$5.7M4929%N/AN/A
#10
$13.6M9442%N/AN/A
Add Company

What Is PFS Group S.L.?

Nuestra trayectoria se inicia en 1999 y hoy somos una compañía especializada en el mercado español en materia de Riesgo de Crédito y Recuperaciones. Somos una empresa que orienta su actividad a la búsqueda de soluciones en la gestión del Riesgo de Crédito y Recuperaciones de las entidades financieras. Cada proyecto en el que participamos se distingue de los otros , ya que recibe un tratamiento único y es adaptado a las necesidades y circunstancias de nuestros clientes. Cuidar a las personas es uno de los objetivos de PFS Group, así como retener el talento. Nuestras políticas y planes personalizados nos permiten atender las necesidades individuales y adaptarnos a las características de todos.

keywords:N/A

N/A

Total Funding

338

Number of Employees

$61.3M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

PFS Group S.L. News

2022-04-17 - Significance of Pre-Chemoradiotherapy Platelet-to-Albumin ...

As shown in Table 3, the 5-year PFS and OS rates were likewise inferior in the PAR?4.9, CA 19–9 90 U/mL, and node-positive patients groups (...

2022-04-13 - Ribociclib in the Treatment of Breast Cancer | BCTT

Results from the MONALEESA-7 trial also show a significantly longer duration of PFS in the RIBO group than in the placebo group; the median...

2022-04-06 - Stem cell transplant for mantle cell lymphoma in Taiwan ...

Patients receiving transplant at their CR1 state had better PFS and OS. ... which the rituximab group had superior event-free survival, PFS,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$137.3M33826%N/A
#2
N/A3426%N/A
#3
$62.2M343-20%N/A
#4
$64.5M3449%N/A
#5
$60.4M3456%N/A